Drugs / LY007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06279611 | Dec 2021 → Aug 2024 | B-cell non-Hodgkin lymphoma | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06364852 | Dec 2021 → Aug 2024 | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364852 ↗ |
| Modality | Cell therapy | “The CAR T cell preparation to be evaluated in this study is LY007” NCT06279611 ↗ |